Nkarta (NKTX) Revenue (2019)
Nkarta (NKTX) posted quarterly Revenue of -$385.0 for Q3 2019, down 116.68% quarter-over-quarter from $2308.0 in Q2 2019.
Nkarta (NKTX) Revenue (2019) Analysis & Trends
Nkarta's Revenue history runs 1 years deep, the most recent figure standing at -$385.0 for Q3 2019.
- In Q3 2019, Revenue changed N/A year-over-year to -$385.0; the TTM figure through Dec 2020 stood at -$385.0 (changed N/A YoY), while the FY2019 annual figure was $115000.0, changed N/A from the prior year.
- Revenue for Q3 2019 stood at -$385.0, down from $2308.0 in the prior quarter.
- The five-year high for Revenue was $2308.0 in Q2 2019, with the low at -$385.0 in Q3 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 145.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.71 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.29 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 1.06 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 425.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 674.14 Mn |
| 10 | Nkarta | 201.14 Mn | 201.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | -385.00 |
| Jun 30, 2019 | 2,308.00 |